|
| General Information |
| Business: |
We are a clinical-stage biopharmaceutical company focused on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases. Our lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate that we believe has advantages over existing prostate cancer therapies. We have administered galeterone to over 200 prostate cancer patients and healthy volunteers in Phase 1 and Phase 2 clinical trials. In these trials, galeterone was well tolerated and in multiple prostate cancer patient populations showed clinically meaningful reductions in levels of prostate specific antigen, or PSA, a biochemical marker used to evaluate prostate cancer patients for signs of response to therapy. Subject to discussions with the U.S. Food and Drug Administration, or FDA, we anticipate initiating a pivotal clinical trial of galeterone in the first half of 2015. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
17 |
Founded: |
2004 |
|
| Contact Information |
| Address: |
One Broadway, 14th Floor, Cambridge, MA 02142 , US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -19.6 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
TKAI |
| Shares (millions): |
6.5 |
| Price Range: |
$15.00 - $15.00 |
| Est.$ Volume |
$ 97.2 mil |
| Manager / Joint Managers |
BMO Capital Markets/ Stifel/ William Blair |
| Co Managers |
Janney Montgomery Scott |
| Expected to Trade |
9/17/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
